BioCryst Pharmaceuticals, Inc. (BO1.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 09:25AM CEST. Market open.
| Previous close | 4.70 |
| Open | 5.19 |
| Bid | 4.88 x 168000 |
| Ask | 4.98 x 164000 |
| Day's range | 5.19 - 5.19 |
| 52-week range | 3.84 - 8.21 |
| Volume | |
| Avg. volume | 187 |
| Market cap | 1.133B |
| Beta (5Y monthly) | 1.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter Results
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) defied analyst predictions to release its first-quarter results, which...
- Insider Monkey
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23. BCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]
- Simply Wall St.
BioCryst Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
BioCryst Pharmaceuticals ( NASDAQ:BCRX ) First Quarter 2024 Results Key Financial Results Revenue: US$92.8m (up 35...
© 2024 Yahoo. All rights reserved.